Topiramate exhibits anti-tumorigenic and metastatic effects in ovarian cancer cells.

Topiramate exhibits anti-tumorigenic and metastatic effects in ovarian cancer cells. Am J Transl Res. 2018;10(6):1663-1676 Authors: Xu G, Fang Z, Clark LH, Sun W, Yin Y, Zhang R, Sullivan SA, Tran AQ, Kong W, Wang J, Zhou C, Bae-Jump VL Abstract Ovarian cancer is one of the leading causes of cancer related deaths among women worldwide, with an overall 5-year survival of only 30-40%. Carbonic anhydrases are up-regulated in many types of cancer and play an important role in tumor progression and metastasis. Carbonic anhydrase 9 has been implicated as a potential anti-tumorigenic target. Topiramate (TPM) is a potent inhibitor of carbonic anhydrase isozymes, including carbonic anhydrase 9, and has been shown to have anti-tumorigenic activity in several cancer types. Our goal was to evaluate the effect of TPM on cell proliferation and to identify possible mechanisms by which TPM inhibits cell growth in ovarian cancer. TPM significantly inhibited ovarian cancer cell proliferation and induced cell cycle G1 arrest, cellular stress and apoptosis through the AKT/mTOR and MAPK pathways. TPM also exerted anti-metastatic effects by decreasing the adhesion and invasion of ovarian cancer cells and affecting the expression of critical regulators of the epithelial-mesenchymal transition (EMT). Our findings demonstrate that TPM has anti-tumorigenic effects in ovarian cancer and is worthy of further exploration in clinical trials. PMID: 3001870...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research